Flutoprazepam(KB-509)の生体内動態(第4報)イヌにおけるFlutoprazepam-2-^<14>CおよびDesalkylflutoprazepam-2-^<14>Cの血漿中動態
スポンサーリンク
概要
- 論文の詳細を見る
The pharmacokinetics of flutoprazepam (FP) and its major metabolite, desalkylflutoprazepam (DFP), was studied in dogs. Two tenth mg/kg flutoprazepam-2-^<14>C were administered intravenously and oraly, and 0.2 mg/kg desalkylflutoprazepam-2-^<14>C were administered intravenously to each of three dogs, respectively. The plasma levels of FP or DFP after bolus intravenous injection declined biexponentially and the hybrid pharmacokinetic parameters were estimated as follows (value for parameter±standard error) : A=111.4±43.4 ng/ml, B=21.9±7.3 ng/ml, α=0.0522±0.255 min^<-1>, β=0.00507±0.00116 min^<-1> for FP ; A=109.2±44.9 ng/ml, B=121.7±38.5 ng/ml, α=0.0455±0.0374 min^<-1>, β=0.00999±0.00139 min^<-1> for DFP. The first order absorption with a rate constant of 0.069 min^<-1> was recognized by an application of the Loo-Riegelman method to FP plasma level vs. time data after oral administration. The time course of plasma levels of the active metabolite, DFP, after oral and intravenous administration of FP exhibited in parallel with those of intact drug in terminal phase. The apparent elimination of DFP in the terminal phase could be regarded as being reflected by that of FP, since the inherent β-value for DFP was larger than that for FP. Therefore, it suggests that an administration of FP may prolong the pharmacological efficacies.
- 公益社団法人日本薬学会の論文
- 1982-12-25
著者
-
粟田 則男
Department Of Formulation Research Pharmaceuticals Research Center Kanebo Ltd.
-
粟田 則男
鐘紡株式会社 薬品開発第一研究所
-
粟田 則男
Product Research And Development Laboratories Pharmaceuticals Research Center Kanebo Ltd.
-
桜井 修一
Department of Formulation Research, Pharmaceuticals Research Center, Kanebo, Ltd.
-
桜井 修一
鐘紡株式会社 薬品研究所
-
小崎 章夫
鐘紡株式会社薬品研究所
-
桜井 修一
Department Of Formulation Research Pharmaceuticals Research Center Kanebo Ltd.
関連論文
- Identification of Nifedipine Metabolites and Their Determination by Gas Chromatography
- Immunoaffinity Extraction of 4-Hydroxy-2-(4-methylphenyl) benzothiazole and Its Metabolites for Determination by Gas Chromatography-Mass Spectrometry
- 塩酸アセブトロールの多形
- Dehydroepiandrosterone Sulfate の家兎における吸収, 排泄および代謝
- 乙字湯エキス粉末のラット胎児器官形成期経口投与試験
- 加味帰脾湯エキス粉末のラット胎児器官形成期経口投与試験
- 加味帰脾湯エキス粉末のラットにおける3ヵ月間反復経口投与毒性試験
- 人参養栄湯エキス粉末のラットにおける3ヵ月間反復経口投与毒性試験
- High-Performance Liquid Chromatographic Determination of Ferulic Acid in Plasma
- Absorption and Metabolism of γ-Oryzanol in Rats
- Mass Fragmentographic Determination of Ferulic Acid in Plasma after Oral Administration of γ-Oryzanol
- 家兎におけるγ-Oryzanolの代謝
- Determination of the Antiallergic Agent KB-2413 in Plasma by Means of Capillary Gas Chromatography with a Nitrogen-Sensitive Detector
- 塩酸ロメリジン(KB-2796)のラットにおける代謝
- Contributions of Various Serum Proteins to the Binding of Prasterone Sulfate in Humans
- Hepatic Transport of an Antiallergic Agent, Emedastine Difumarate : Interspecies Difference in Rats and Guinea Pigs
- 抗アレルギー薬フマル酸エメダスチンのラット及びモルモットにおけるin Vitro代謝
- 高速液体クロマトグラフィー/ラジオレセプターアッセイによるヒト血漿中の抗アレルギー薬, フマル酸エメダスチン(KG-2413), の選択的高感度定量
- 抗アレルギー薬1-(2-Ethoxyethyl)-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-1H-benzimidazole Difumarate(KG-2413)のラジオレセプターアッセイにおける活性代謝物の交差性
- 抗アレルギー薬1-(2-Ethoxyethyl)-2-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-1H-benzimidazole Difumarate(KG-2413)のラットにおける代謝物の同定
- Interspecies Differences in Pharmacokinetics of an Antiallergic Agent, 1-(2-Ethoxyethyl)-2-(hexahydro-4-methyl-1,4-diazepin-1-yl)benzimidazole Difumarate (KG-2413) after Intravenous Administration to Rats, Guinea Pigs and Dogs
- キャピラリ-GC/MSによるシアニダノ-ルの代謝研究 (GC/MS特集)
- Determination of the Antiplatelet Agent, KB-3022,and Its Metabolite by High-Performance Liquid Chromatography
- ガスクロマトグラフ法による新規抗血小板薬KBT-3022の主代謝物(Desethyl KBT-3022)の血漿中微量定量
- 〔3-2H〕-および〔3-3H〕-シアニダノ-ルの合成
- Dehydroepiandrosterone Sulfateのin Vitro代謝(第1報)ヒトおよびサル妊娠末期胎盤における代謝
- 補中益気湯エキス粉末のラット胎児器官形成期経口投与試験
- Flutoprazepam(KB-509)の生体内動態(第4報)イヌにおけるFlutoprazepam-2-^CおよびDesalkylflutoprazepam-2-^Cの血漿中動態
- タイトル無し